[go: up one dir, main page]

BR112012013139A2 - oligopeptídeos imp-3 e vacinas incluindo os mesmos - Google Patents

oligopeptídeos imp-3 e vacinas incluindo os mesmos

Info

Publication number
BR112012013139A2
BR112012013139A2 BR112012013139A BR112012013139A BR112012013139A2 BR 112012013139 A2 BR112012013139 A2 BR 112012013139A2 BR 112012013139 A BR112012013139 A BR 112012013139A BR 112012013139 A BR112012013139 A BR 112012013139A BR 112012013139 A2 BR112012013139 A2 BR 112012013139A2
Authority
BR
Brazil
Prior art keywords
oligopeptides
imp
same
cytotoxic
vaccines including
Prior art date
Application number
BR112012013139A
Other languages
English (en)
Inventor
Michiko Harao
Takuya Tsunoda
Yasuharu Nishimura
Yusuke Nakamura
Yusuke Tomita
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BR112012013139A2 publication Critical patent/BR112012013139A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

oligopeptídeos imp-3 e vacinas incluindo os mesmos. a presente invenção refere-se a oligopeptídeos que possuem capacidade de indução de célula t citotóxica e são adequados para uso no contexto da imunoterapia do câncer, mais particularmente, vacinas para o câncer. exemplos notáveis incluem oligopeptídeos que têm a sequência de aminoácido de seq id no: 1, 3, 5 ou 6, em que 1, 2, ou vários aminoácidos são opcionalmente substituídos, deletados, inseridos ou adicionais, contato que eles guardem a capaciade de indução de célula t citotóxica dos oligopeptídeos originais.formulações farmacêuticas ou ''fármacos'' relacionados a tais olipeptídeos adequados para o tratamento ou a prevenção de cânceres ou tumores, assim como a recorrência pós-operatória dos mesmos, também são descritos.
BR112012013139A 2009-12-01 2010-11-30 oligopeptídeos imp-3 e vacinas incluindo os mesmos BR112012013139A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26565709P 2009-12-01 2009-12-01
US37143410P 2010-08-06 2010-08-06
PCT/JP2010/006966 WO2011067920A1 (en) 2009-12-01 2010-11-30 Imp-3 oligopeptides and vaccines including the same

Publications (1)

Publication Number Publication Date
BR112012013139A2 true BR112012013139A2 (pt) 2016-10-11

Family

ID=44114782

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013139A BR112012013139A2 (pt) 2009-12-01 2010-11-30 oligopeptídeos imp-3 e vacinas incluindo os mesmos

Country Status (14)

Country Link
US (1) US20120308590A1 (pt)
EP (1) EP2507256A4 (pt)
JP (1) JP2013511958A (pt)
KR (1) KR20120099106A (pt)
CN (1) CN102741271B (pt)
AU (1) AU2010327878B2 (pt)
BR (1) BR112012013139A2 (pt)
CA (1) CA2782271A1 (pt)
IL (1) IL219976A0 (pt)
MX (1) MX2012006126A (pt)
RU (1) RU2550695C2 (pt)
SG (2) SG181107A1 (pt)
TW (1) TW201124530A (pt)
WO (1) WO2011067920A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
TWI627182B (zh) * 2013-05-24 2018-06-21 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗
BR112017002206A2 (pt) * 2014-08-04 2017-11-21 Oncotherapy Science Inc peptídeo derivado de koc1 e vacina incluindo o mesmo
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
PT3430037T (pt) * 2016-03-16 2022-11-23 Immatics Biotechnologies Gmbh Células t transfetadas e recetores de células t para uso em imunoterapia anticancro
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
CN110191703B (zh) 2017-01-25 2022-04-08 奥塞免疫疗法公司 用于肽递送的稳定乳液的制造方法
AU2018389346B2 (en) * 2017-12-23 2022-08-25 Rubius Therapeutics, Inc. Artificial antigen presenting cells and methods of use
CN114853847B (zh) * 2022-06-29 2022-09-27 中国农业大学 辣椒籽分离的寡肽ftle及其在预防或治疗癌症中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
WO2002020036A1 (de) * 2000-09-06 2002-03-14 Mueller Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
PT2325306E (pt) * 2005-02-25 2014-04-29 Oncotherapy Science Inc Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1
US10611818B2 (en) * 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
RS53782B1 (en) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers

Also Published As

Publication number Publication date
SG10201407944TA (en) 2015-01-29
KR20120099106A (ko) 2012-09-06
RU2012127358A (ru) 2014-01-10
EP2507256A1 (en) 2012-10-10
SG181107A1 (en) 2012-07-30
US20120308590A1 (en) 2012-12-06
EP2507256A4 (en) 2013-10-16
RU2550695C2 (ru) 2015-05-10
IL219976A0 (en) 2012-07-31
TW201124530A (en) 2011-07-16
MX2012006126A (es) 2012-06-19
CA2782271A1 (en) 2011-06-09
AU2010327878B2 (en) 2014-11-20
JP2013511958A (ja) 2013-04-11
AU2010327878A1 (en) 2012-06-21
CN102741271B (zh) 2014-11-05
WO2011067920A1 (en) 2011-06-09
CN102741271A (zh) 2012-10-17

Similar Documents

Publication Publication Date Title
BR112012013139A2 (pt) oligopeptídeos imp-3 e vacinas incluindo os mesmos
ES2781454T3 (es) Nuevo complejo que comprende un péptido de penetración celular, una molécula de carga y un agonista peptídico de TLR para el tratamiento del cáncer colorrectal EpCAM
PH12014501642B1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
IL265479B (en) Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
IN2014DN09963A (pt)
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
PH12014500720A1 (en) Topk peptides and vaccines including the same
BR112013031056A2 (pt) peptídeos de sema5b e vacinas incluindo os mesmos
EP3208334A3 (en) Cdc45l peptides and vaccines including the same
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
BR112012022641A2 (pt) peptídeos hjurp e vacinas que incluem os mesmos
EA201291004A1 (ru) Пептиды ect2 и включающие их вакцины
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos
BR112012013371A2 (pt) peptídeo mybl2 e vacinas contendo os mesmos.
EP4047009A3 (en) Wdrpuh epitope peptides and vaccines containing the same
PH12012501935A1 (en) Ect2 peptides and vaccines including the same
TH158366A (th) Topk เปปไทด์ และวัคซีนที่รวมถึงสิ่งเดียวกันนั้น

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]